Cargando…
Challenges facing the clinical adoption of a new prognostic biomarker: a case study
In this article, we show how a particular biomarker comes into being in an emergency department in a hospital in Copenhagen, Denmark. We explore the contextual becoming of this biomarker, suPAR, through interviews with nurses and physicians and through relational ontology. We find that as a prognost...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Palgrave Macmillan UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860228/ https://www.ncbi.nlm.nih.gov/pubmed/36713027 http://dx.doi.org/10.1057/s41292-022-00296-2 |
_version_ | 1784874533886361600 |
---|---|
author | Larsen, Trine Schifter Eugen-Olsen, Jesper Andersen, Ove Kirk, Jeanette Wassar |
author_facet | Larsen, Trine Schifter Eugen-Olsen, Jesper Andersen, Ove Kirk, Jeanette Wassar |
author_sort | Larsen, Trine Schifter |
collection | PubMed |
description | In this article, we show how a particular biomarker comes into being in an emergency department in a hospital in Copenhagen, Denmark. We explore the contextual becoming of this biomarker, suPAR, through interviews with nurses and physicians and through relational ontology. We find that as a prognostic biomarker suPAR is challenged in it becoming as an object for clinical practice in the emergency department by the power of diagnostic practices and the desire for experience-based scripts that quickly enable the clinician to reach the right diagnosis. Although suPAR is enacted as a promising triage strategy suggesting a low or high risk of disease, the inability to rule out specific diagnoses and producing the notion of secure clinical actions make its non-specificity and prognostic character problematic in clinical practices. Specific diagnostic criteria versus prognostic interpretation and non-specificity risk profiling challenges the way healthcare workers in an emergency department understand the tasks they are set to solve and how to solve them. We discuss how the becoming of suPAR is strengthened through enactments of specificity and engagement in triage strategies and we reflect on it’s becoming through new diagnostic practices with the need to accommodate diagnostic ambiguity. |
format | Online Article Text |
id | pubmed-9860228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Palgrave Macmillan UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98602282023-01-23 Challenges facing the clinical adoption of a new prognostic biomarker: a case study Larsen, Trine Schifter Eugen-Olsen, Jesper Andersen, Ove Kirk, Jeanette Wassar Biosocieties Original Article In this article, we show how a particular biomarker comes into being in an emergency department in a hospital in Copenhagen, Denmark. We explore the contextual becoming of this biomarker, suPAR, through interviews with nurses and physicians and through relational ontology. We find that as a prognostic biomarker suPAR is challenged in it becoming as an object for clinical practice in the emergency department by the power of diagnostic practices and the desire for experience-based scripts that quickly enable the clinician to reach the right diagnosis. Although suPAR is enacted as a promising triage strategy suggesting a low or high risk of disease, the inability to rule out specific diagnoses and producing the notion of secure clinical actions make its non-specificity and prognostic character problematic in clinical practices. Specific diagnostic criteria versus prognostic interpretation and non-specificity risk profiling challenges the way healthcare workers in an emergency department understand the tasks they are set to solve and how to solve them. We discuss how the becoming of suPAR is strengthened through enactments of specificity and engagement in triage strategies and we reflect on it’s becoming through new diagnostic practices with the need to accommodate diagnostic ambiguity. Palgrave Macmillan UK 2023-01-21 /pmc/articles/PMC9860228/ /pubmed/36713027 http://dx.doi.org/10.1057/s41292-022-00296-2 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Article Larsen, Trine Schifter Eugen-Olsen, Jesper Andersen, Ove Kirk, Jeanette Wassar Challenges facing the clinical adoption of a new prognostic biomarker: a case study |
title | Challenges facing the clinical adoption of a new prognostic biomarker: a case study |
title_full | Challenges facing the clinical adoption of a new prognostic biomarker: a case study |
title_fullStr | Challenges facing the clinical adoption of a new prognostic biomarker: a case study |
title_full_unstemmed | Challenges facing the clinical adoption of a new prognostic biomarker: a case study |
title_short | Challenges facing the clinical adoption of a new prognostic biomarker: a case study |
title_sort | challenges facing the clinical adoption of a new prognostic biomarker: a case study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860228/ https://www.ncbi.nlm.nih.gov/pubmed/36713027 http://dx.doi.org/10.1057/s41292-022-00296-2 |
work_keys_str_mv | AT larsentrineschifter challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy AT eugenolsenjesper challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy AT andersenove challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy AT kirkjeanettewassar challengesfacingtheclinicaladoptionofanewprognosticbiomarkeracasestudy |